Patrick Hagen

[Patrick Hagen @HagenPatrick81]

doi: 10.1002/ajh.27484. Online ahead of print.. 2024 Sep https://t.co/qlC9Fdodbf J Hematol
FDA IDE validation of multiple myeloma MRD test by flow cytometry

PMID: 39291868
DOI: 10.1002/ajh.27484

[Patrick Hagen @HagenPatrick81]

I am struck by the brevity of this correspondence in comparison to the amount of work required to validate and secure FDA approval for NGF based MRD testing as a stratification factor (and in the future and endpoint!) on a large cooperative group trial!

[Patrick Hagen @HagenPatrick81]

MRD based interventions, stratification, and endpoints are the present and future of MM research and this paves the way for future efforts in this space

[Patrick Hagen @HagenPatrick81]

@bdermanmd

[Patrick Hagen @HagenPatrick81]

@bdermanmd Put them on s2213! The SWOG trial evaluating the role of transplant. We don't know the optimal endpoint in AL... CR sounds great but data is clear that mrd negativity in the BM by NGF or NGS and in the peripheral blood by mass spec leads to improved outcomes across the board.

[Patrick Hagen @HagenPatrick81]

@bdermanmd

[SWOG Cancer Research Network @SWOG]

Re-opened! @SWOG S2005: randomized ph 2 now compares venetoclax + rituximab to usual treatment of ibrutinib + rituximab in untreated #Waldenström's #macroglobulinemia or #lymphoplasmacytic #lymphoma.
https://t.co/QbrGHXpnC7
PI: Sikander Ailawadhi, MD @MayoClinic @Myeloma_Doc

[Patrick Hagen @HagenPatrick81]

Thrilled to be at ISA 2024 sharing the recently opened S2213 evaluating the role of high dose chemotherapy and stem cell transplant in the daratumumab era!